The German biotechnology company also plans to establish a fully integrated messenger RNA (mRNA) manufacturing facility in the republic with support from the Singapore Economic Development Board.
"Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” said its Chief Executive and Co-founder, Ugur Sahin, in its website.
"With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” he said.
The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for southeast Asia to address potential pandemic threats.
BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval.
The company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.
BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
BioNTech is among the handful of biotechnology companies that has succeeded in producing the COVID-19 vaccine which boasts for 95 percent efficacy rate. - Bernama